CD274 and non-small cell lung carcinoma: The results demonstrated that in cases of PD-L1-nonselective NSCLC, the group receiving nivolumab combined with ipilimumab exhibited improved progression-free survival (PFS) and objective response rate (ORR), while pembrolizumab notably prolonged patients' overall survival (OS).